白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效与安全性分析

Efficacy and Safety of Abraxane and Paclitaxel Liposome in Treatment of Recurrent Ovarian Cancer

目的：探讨白蛋白结合型紫杉醇（P11X）与PTX脂质体（力扑素）治疗复发性卵巢癌的近期疗效及不良反应。方法：回顾性分析采用PTX治疗的90例复发性卵巢癌患者的临床资料，其中应用白蛋白结合型PTX联合奈达铂治疗30例为PTX结合型组，应用PTX脂质体联合奈达铂治疗60例为P11）（脂质体组。比较两组癌抗原125（CAl25）下降情况和肿瘤病灶缩小情况，以及不良反应的差异。结果：PTX结合型组CA协下降的有效率（63．3％）高于P1x脂质体组（41．7％）；PTX结合型组病灶缩小的有效率（54．5％）高于PTX脂质体组（23．8％），差异均有统计学意义（P〈0．05）。PTX结合型组腹泻、呕吐、白细胞减少Ⅲ～Ⅳ级的不良反应发生率均少于PTX脂质体组（P〈0．05），两组神经毒性发生率比较，差异无统计学意义（19〉0．05）。结论：白蛋白结合型PTX联合奈达铂与PTX脂质体联合奈达铂治疗复发性卵巢癌相比，其临床近期疗效提高，严重不良反应率较低，使用方便，值得推广。

Objective： To compare the efficacy and adverse reactions of Abraxane and paclitaxel liposome （force simplicity）in treatment of recurrent ovarian cancer. Methods：Retrospective analysis of 90 cases of recur- rent ovarian cancer treated with PTX, including 30 cases with albumin bound PTX combined with nedaplatin（ PTX combined type group）, and 60 cases with application of PTX liposome combined with nedaplatin （PTX liposome group）. Results：The efficiency of CA125decrease in PTX combined type group（63.3%）was higher than that in PTX liposome group （41.7%） （ P 〈 0. 05）. The efficiency of lesion size reduction in PTX combined type group （54. 5% ） was higher than that in PTX liposome group （23.8%） （P 〈0. 05）. The incidence of Ⅲ - IV grade ad- verse events,including diarrhea, vomiting, and decrease of white blood cells, in PTX combined type group was less than that in PTX liposome group（ P 〈0. 05）. There was no significant difference in the number of neurotoxic cases after inspection between two groups（ P 〉0.05）. Conclusions：Compared with the PTX liposome combined with nedaplatin, the abraxane combined with nedaplatin improved the clinical efficacy, and decreased the inci- dence of serious adverse reaction in treatment of recurrent ovarian cancer.